⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MBRX News
Moleculin Biotech, Inc.
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Form 8-K
sec.gov
MBRX
Moleculin Announces Reverse Stock Split
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Form 8-K
sec.gov
MBRX
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX